If you need more lookups,
subscriptions start at $34 USD/month.
Detlev Biniszkiewicz Location
Boston, MA, US
Detlev Biniszkiewicz Work
Managing Director and Investment Partner - MPM Innovation Fund @ (January 2020 - Present)
Founder, Chairman, and Former CEO - NextPoint Therapeutics @ (January 2018 - January 2024)
Founder, President and CEO - Sieben Therapeutics @ (January 2020 - January 2023)
Founder, Chairman of the Board @ (January 2022 - Present)
Founder, CEO, and President @ (January 2018 - April 2023)
Board of Directors - Independent @ (January 2019 - January 2024)
Board of Directors @ (January 2019 - January 2023)
Board of Directors @ (January 2018 - January 2021)
Detlev Biniszkiewicz Education
Massachusetts Institute of Technology
Doctor of Philosophy (Genetics)
1996-2001
Detlev Biniszkiewicz Skills
Biomarkers
Biopharmaceuticals
Biotechnology
Business Strategy
Cancer
Cell Biology
Clinical Development
Clinical Research
Clinical Trials
Commercialization
Cross-functional Team Leadership
Drug Development
Drug Discovery
Genetics
Genomics
Immunology
Leadership
Life Sciences
Lifesciences
Oncology
Pharmaceutical Industry
Strategy
Technology Transfer
Customer Service
Risk Management
Project Management
Microsoft Office
Customer Experience Planning
Technology Marketing
Cross Functional Team Leadership
Product Launch
Retail Experience Design
Detlev Biniszkiewicz Summary
Detlev Biniszkiewicz, based in Boston, MA, US, is currently a Managing Director and Investment Partner - MPM Innovation Fund at MPM BioImpact. Detlev Biniszkiewicz brings experience from previous roles at MPM BioImpact and NextPoint Therapeutics, Inc.. Detlev Biniszkiewicz holds a 1996 - 2001 Doctor of Philosophy in Genetics @ Massachusetts Institute of Technology. With a robust skill set that includes Biomarkers, Biopharmaceuticals, Biotechnology, Business Strategy, Cancer and more. Detlev Biniszkiewicz has 3 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Detlev Biniszkiewicz?
Find contact details for 700 million professionals.